title: The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
authors.forename: Anthony W
authors.initials: AW
authors.lastname: Tolcher
authors.forename: Chris H
authors.initials: CH
authors.lastname: Takimoto
authors.forename: Eric K
authors.initials: EK
authors.lastname: Rowinsky
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D017321:Clinical Trials, Phase I as Topic; D023381:Endpoint Determination; D000077156:Gefitinib; D006801:Humans; D007400:Interprofessional Relations; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy; D010819:Physician's Role; D011799:Quinazolines / Q000009:adverse effects / Q000494:pharmacology; D012107:Research Design
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib